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Streptococcal fibronectin-binding protein is an important virulence factor involved in colonization and
invasion of epithelial cells and tissues by Streptococcus pyogenes. In order to investigate the mechanisms
involved in the evolution of sfbI, the sfbI genes from 54 strains were sequenced. Thirty-four distinct alleles were
identified. Three principal mechanisms appear to have been involved in the evolution of sfbI. The amino-
terminal aromatic amino acid-rich domain is the most variable region and is apparently generated by
intergenic recombination of horizontally acquired DNA cassettes, resulting in a genetic mosaic in this region.
Two distinct and divergent sequence types that shared only 61 to 70% identity were identified in the central
proline-rich region, while variation at the 3 end of the gene is due to deletion or duplication of defined repeat
units. Potential antigenic and functional variabilities in SfbI imply significant selective pressure in vivo with
direct implications for the microbial pathogenesis of S. pyogenes.
Streptococcal fibronectin-binding protein I (SfbI), also
known as protein F1, is probably the most extensively charac-
terized fibronectin-binding protein in group A streptococcus
(GAS; Streptococcus pyogenes). Identified simultaneously in
two independent laboratories (15, 39), SfbI is a membrane-
anchored surface protein shown to be a major adhesin of GAS
(13, 15, 28, 29, 39, 42). In addition, SfbI binds to fibrinogen via
a domain in the amino terminus (20) and human immunoglob-
ulin (IgG) via the carboxy-terminal fibronectin-binding repeat
domain (25). SfbI is protective in mice (14, 34) and a mucosal
adjuvant (26). According to various reports, it is present in 64
to 82% of strains (13, 22, 28). Beside its ability to mediate
adherence to host cells via binding to fibronectin as a bridging
molecule, SfbI is a potent invasin of epithelial cells (16, 27).
While efficient adhesion is mediated through the fibronectin-
binding repeat region, internalization into host cells is gov-
erned by the fibronectin-binding spacer region in a cooperative
manner (41). Recent work demonstrates that SfbI-induced in-
tegrin clustering initiates caveola recruitment and subsequent
caveola-mediated uptake of the pathogen into epithelial and
endothelial cells (33). The interaction between the fibronectin-
binding repeat region and the N-terminal F1 modules of fi-
bronectin has been elegantly resolved by defining the structure
of the complex that is formed (35). Another important and
recently identified function of SfbI is the ability to recruit
collagen via prebound fibronectin. SfbI thereby mediates bac-
terial aggregation, colonization of the collagen matrix, and
phagocyte evasion (9). SfbI, like many membrane-associated
streptococcal proteins, has a repetitive structure and exhibits
decreasing variability from the amino terminus to the carboxy
terminus (40). The protein is synthesized as a propeptide with
a signal sequence at the amino terminus of the protein which
is subsequently cleaved to form the mature protein. The amino
terminus of the mature protein contains a domain rich in
aromatic amino acids, adjacent to which is a proline-rich do-
main. The proline-rich domain is made up of two regions: the
proline-rich repeats and the proline-rich upstream region en-
compassing the region previously described as proline-rich re-
peats 1 and 2 (40). Toward the carboxy terminus lie two func-
tional fibronectin-binding domains: the fibronectin-binding
repeat domain and a second fibronectin-binding domain which
lies upstream of the fibronectin-binding repeats and which has
been designated spacer 2 (40) or the upstream fibronectin-
binding domain (36). These domains are highly conserved and
display variability only in the number of fibronectin-binding
repeats, which may range from one to six (28, 42). Variable
numbers of proline-rich repeats have also been reported; how-
ever, no correlation between variation in this domain and the
numbers of fibronectin-binding repeats has been found (42).
The carboxy terminus consists of a wall-associated region, a
membrane anchor motif (LPATGD), and a membrane-associ-
ated region rich in hydrophobic residues, all of which are
typical of surface proteins of gram-positive cocci (11).
Several groups have described the arrangement of the
genomic region containing the gene encoding SfbI (6, 30). This
locus has been designated the fibronectin-collagen-T antigen
(FCT) region (6) since it may contain genes encoding the
fibronectin-binding protein SfbI and/or protein F2, a collagen-
binding protein (Cpa), and the T antigen. Incorporation of
sequences from the recently completed M3 (4), M5 (http:
//www.sanger.ac.uk/Projects/S_pyogenes), and M18 (37) ge-
nomes reveals a complex gene arrangement in this region
which is indicative of a zone of frequent genetic rearrange-
ment.
Mosaic alleles are made up of distinct DNA cassettes of
different phylogenic origins which have recombined to produce
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novel chimeric genes. While gene mosaic structures for genes
encoding streptokinase (19), hyaluronidase (24), streptococcal
superantigen (32), and a novel collagen-like protein called
SclA (31) have been reported in GAS, the classic example in
GAS are members of the M-protein family encoded by genes
within the Vir (or mga) regulon (43). Horizontal transfer and
intergenic recombination have played major roles in the evo-
lution of the emm-like family, contributing to both sequence
variation and variation in the overall architecture of the Vir
regulon (44). Since different members of the M-protein family
exhibit different protein-binding capabilities, this rearrange-
ment may have direct ramifications for the virulence and tro-
pisms of the various strains. This is supported by the observa-
tion that different architectural arrangements (emm pattern
types) have been associated with preferences for specific tissue
sites (5).
Although evaluation of the accumulation of mutations is a
valuable tool for assessment of strain relatedness, transfer of
whole cassettes of DNA between strains complicates such anal-
yses. Multilocus sequence typing with several presumably se-
lection-neutral housekeeping genes has been used to deter-
mine the extent of intergenic recombination in bacterial
genomes. The lack of congruence between maximum-likeli-
hood trees for each of the “neutral” genes in GAS was indic-
ative of very high rates of recombination, and it was concluded
that this was sufficient to “obliterate the phylogenetic signal in
[individual] gene trees” (10).
Recombination at distal sites such as the Vir regulon and the
FCT region is most likely independent. Evidence to support
this theory includes the fact that T types do not always conform
to M types, with several T types reported for isolates of the
same M type and vice versa (2, 17). In addition, while the
distribution of sfbI within M types (28) or Vir types (VTs) (13)
is generally consistent, there is evidence of heterogeneity of
sfbI species within M types, as the number of fibronectin-
binding repeats detected in M8 and M28 serotype strains is
variable (28). Significant heterogeneity in sfbI sequences en-
coding the amino-terminal half of the aromatic amino acid-rich
domain from M4, M12, M15, and M18 strains has also been
reported (20).
The aim of this study was to examine precisely the genetic
variability in the entire sfbI in order to determine possible
mechanisms involved in the evolution of this important strep-
tococcal adhesin and invasin. Additionally, we have examined
whether particular sfbI sequence types (STs) are associated
with the clinical source of the isolates.
(Part of this work was presented at the XVth Lancefield
International Symposium on Streptococci and Streptococcal
Disease, October 2002, Goa, India [R. Towers, M. J. Walker,
and G. S. Chhatwal, Lancefield Int. Symp. Streptococci Strep-
tococcal Dis. abstr. O5.3, 2002].)
MATERIALS AND METHODS
Bacterial strains. Isolates were obtained from the Menzies School of Health
Research streptococcal collection. This collection contains isolates from patients
of the Royal Darwin Hospital and the surrounding Aboriginal communities. In
addition, an M13 GAS reference strain from the United Kingdom (Cathy13) and
the homologous sfbII strain (strain 75401) from Germany were included (22, 38).
Background information regarding clinical details, VTs (12), and emm STs (3),
when available, are included in Table 1. All streptococcal strains were grown on
agar plates containing 5% sheep blood (Sigma) at 37°C overnight.
PCR. The template for PCR was prepared by using the InstaGene matrix
(Bio-Rad) according to the instructions of the manufacturer, except that due to
the small size of the streptococcal colonies, 10 to 20 streptococcal colonies were
used. The sequencing template was amplified with primers sfbI-F1 and sfbI-R4.
Each 50-l PCR mixture contained 5 l of InstaGene preparation. The PCR
parameters used were an initial denaturing step at 94°C for 2 min and then 35
cycles of denaturation at 94°C for 1 min, annealing at 49°C for 1 min, and
extension at 72°C for 2 min 30 s, with a final extension step of 72°C for 5 min.
Screening for sfbI and rofA. Many of the data on the distribution of sfbI in the
GAS strains used in this study have been published elsewhere (8, 13). For the
purposes of this study all strains were retested for the presence of sfbI by PCR,
and the results were compared with previous results. PCR screening was per-
formed with primers sfbI-F1 and sfbI-R3. The number of fibronectin-binding
repeats was determined with primers sfbI-F4 and sfbI-R3. Isolates were also
screened for the presence of rofA with primers rofA-F and rofA-R. The arrange-
ment of rofA, relative to that of sfbI, was determined with primers rofA-R and
sfbI-R6. All primer sequences are shown in Table 2, while their positions relative
to those of the respective genes are shown in Fig. 1A.
DNA sequence analysis. The PCR product was used as the template for
sequencing reactions. This template was generated with primers sfbI-F1 and
sfbI-R4 or sfbI-R3. A total of 5 l of the PCR product was visualized in an
ethidium bromide-stained 1% agarose gel to determine its purity and relative
concentration. The remainder was purified with QIAquick columns (Qiagen),
eluted in 30 l of sterile distilled water, and stored at 20°C. The primers used
for the sequence reactions are shown in Table 2.
Sequence alignment was performed with a range of DNASTAR programs.
Applied Biosystems electropherograms were aligned to generate DNA contigs by
using SeqManII, and then DNA contigs were translated to amino acid sequences
with the MegAlign program and were subsequently aligned by the Clustal V
method. The alignment was then modified by eye before being converted back to
the DNA sequence alignment.
Nucleotide sequence accession numbers. The nucleotide sequences for the 54
sfbI genes can be found in the GenBank database under accession numbers
AJ347791 to AJ347844.
RESULTS
Screening for sfbI and rofA. The presence of sfbI was con-
firmed by PCR for 54 GAS isolates. Representative PCR re-
sults are shown in Fig. 1B. PCR was also used to determine the
number of fibronectin-binding repeats as an initial indicator of
variation (Fig. 1C). In addition, the relative distribution and
arrangement of rofA with respect to those of sfbI were estab-
lished by PCR. All strains were tested for the presence of rofA
with primers rofA-F and rofA-R (30) (Fig. 1D), while primers
rofA-R and sfbI-R6 were used to detect adjacent rofA and sfbI
genes (Fig. 1E). rofA was present in all 54 strains and was
situated immediately upstream of sfbI, but in an orientation
opposite that shown in Fig. 1A.
Sequence analysis of sfbI. The entire sfbI gene was amplified
by PCR for use as the sequencing template from most strains
by using primers sfbI-F1 and sfbI-R4. Initially, the sfbI PCR
products from 20 strains were sequenced in their entirety in
both directions. It was determined from these data that the 3
end of sfbI was highly conserved, apart from the various num-
bers of proline-rich and fibronectin-binding repeats. As the
number of fibronectin-binding repeats could be readily deter-
mined by PCR (Fig. 1C) and these results were consistent with
preliminary DNA sequence data, no attempt was made to
sequence the fibronectin-binding repeat domains for the addi-
tional 34 strains examined in this study, and conclusions as to
the relatedness of the genes were drawn from the sequence
and PCR results combined.
The nucleotide sequences were aligned with published sfbI
sequences, including those encoding full-length SfbI (Gen-
Bank accession no. X67947) (2); protein F1 (GenBank acces-
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TABLE 1. Summary of sfbI STs
sfbI ST Strain Clinical source Diseasea VT emm ST Aro type Pro typeb No. of Pro rptsc No. of Fn rptsd
1 NS678 Throat N 33.2 NDe 1 A1 2 1
1 NS704 Throat N 33.2 ND 1 A1 2 1
2 NS1045 Skin N 89 emm60 1 A1 1 2
2 NS1053 Blood I 89 emm60 1 A1 1 2
3 NS1036 Skin N 33.1 emm110 1 A1 1 4
4 BSB19 Skin N 6 stbsb19 2 A1 5 3
5 NS473 Skin N 37.1 stns554 2 A1 1 4
6 NS539 Skin N 1 emm22 2 A1 3 4
7 NS35 Skin N 22 emm58 2 A1 2 4
7 NS351 Skin N 22 emm58 2 A1 2 4
7 NS474 Skin N 22 emm58 2 A1 2 4
7 NS687 Blood I 22 emm58 2 A1 2 4
8 BL16 Skin N 25 emm85 2 A2 4 1
9f D471 Throat N ND (M6)g 3 A1 1 5
10 NS691 Skin N 57 emm69 4 A1 1 4
10 NS930 Skin I 57 emm69 4 A1 1 4
10 NS931 Blood I 57 emm69 4 A1 1 4
11 NS16 Skin N 37.1 stns554 5 B1 1 5
11 NS240 Blood I 116 st2904 5 B1 1 5
12 NS190 Skin I 19 emm74 5 B1 1 4
12 DRX5 Skin N 30 ND 5 B1 1 4
13 NS210 Blood I 34 emm22 5 B1 2 3
14 NS1120 Throat N 105 ND 5 B3 5 3
15 NS179 Pus I 7.2 emm9.1 6 B3 11 2
16 NS192 Blood I 3.2 emm100 6 B2 4 4
17 CATHY13 Unknown U 2.1 emm13 6 B1 4 1
17 NS297 Skin N 3.1 emm44/61 6 B1 4 1
17 NS495 Skin N 2.2 emm90 6 B1 4 1
17 NS730 Pus I 2.2 emm90 6 B1 4 1
17 NS731 Pus I 2.2 emm90 6 B1 4 1
17 NS732 Aspirate I 2.2 emm90 6 B1 4 1
17 NS755 Blood I 2.2 emm90 6 B1 4 1
17 NS989 Skin N 2.2 emm90 6 B1 4 1
18 NS226 Blood I 14.1 emm42 7 A1 5 4
18 NS244 Skin N 14.1 stns244 7 A1 5 4
18 NS415 Skin N 14.1 stns244 7 A1 5 4
19 NS14 Skin N 96 emm102 7 A1 4 4
20 NS488 Throat N 52 emm12 8 A2 5 4
20 NS880 Throat N 52 emm12 8 A2 5 4
20 A735 Throat N ND (M12) 8 A2 5 4
21 75401 Throat N ND (M75) 9 B1 2 3
22 NS101 Blood I 33.1 emm110 10 B1 1 3
22 NS516 Skin N 33.1 emm110 10 B1 1 3
23 BSA39 Skin N 7.1 emm63 10 B1 1 5
24 NS1132 Skin N 104 emm25 11 B1 1 3
25 DRV1 Skin N 18 emm55 12 B1 1 4
26 NS216 Blood I 122 ND 12 B1 4 4
27 EF1949 Unknown U ND (M15) 13 A2 5 4
28 NS424 Skin N 61 emm14 13 A2 6 4
28 NS483 Skin N 61 emm14 13 A2 6 4
28 NS501 Blood I 61 emm14 13 A2 6 4
28 NS506 Skin N 61 emm14 13 A2 6 4
29 NS534 Blood I 37.1 stns554 13 A2 3 1
30 DRY5 Skin N 37.1 stns554 13 A2 1 2
31 DSM2071 Unknown N ND (M23) 14 A1 2 4
32 NS90 Blood I 52 stns90 15 B1 1 4
33 NS195 Blood I 120 ND 15 B1 1 5
34 NS1042 Skin N 77 stck401 15 B1 1 2
a Invasive or noninvasive disease: I, invasive; N, noninvasive; U, unknown.
b Pro type, SfbI proline-rich region sequence subtype.
c Pro rpts, “true” proline-rich repeats.
d Fn rpts, fibronectin-binding repeats.
e ND, not determined.
f Boldface indicates information published previously.
g M serotype, as stated in relevant publications.
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sion no. L10919) (20); protein F1.12 (GenBank accession no.
AF447492) (6); protein F15 and 12 partial sfbI sequences
(GenBank accession nos. AF009908 to AF009920) (20); and
gfbA, an sfbI homolog from GGS (GenBank accession no.
U131115) (21). The nucleotide sequence alignment can be
found at GenBank alignment accession number ALIGN
_000212 (data not shown).
Source of variation in sfbI. Figure 2 shows an overall sche-
matic of the variation observed in the sfbI sequences. As noted
previously (40), variation in sfbI decreases in the 5-to-3 di-
rection. The variation at the 3 end of the gene is due to
intragenic recombination, i.e., rearrangement of repetitive el-
ements within genes through homologous recombination. The
deletion or duplication of repeat units (narrower bars in Fig. 2)
has resulted in a variable number of proline-rich and fibronec-
tin-binding repeats. There is no relationship between the num-
bers of proline-rich repeats and the numbers of fibronectin-
binding repeats, nor is there an association between the
numbers of repeats and the upstream sequence variation.
Therefore, it can be assumed that intragenic recombination is
a frequent phenomenon within these regions.
Two distinct and divergent STs which exhibited 61 to 70%
identity in pairwise alignments of the DNA sequences were
identified within the central proline-rich region. These have
been designated ProA and ProB. In addition, defined internal
sequences have been duplicated or deleted, thereby generating
two to three subtypes within each proline-rich region type (Fig.
2 and 3). In the case of ST ProB, in which up to two copies of
the internal sequences were present, these repetitive structures
were designated the ProB repeats.
The 5 end of sfbI, which encodes the aromatic amino acid-
rich domain, is by far the most variable region of the gene.
Fifteen distinct aromatic amino acid-rich domain sequences
types (Aro types), designated Aro1 to Aro15, were identified.
In pairwise alignments, a minimum 98.8% identity was seen
within Aro types, while 50.3 to 97.6% identity was observed
between types. While some of this variation is due to point
TABLE 2. Primer sequences used in this study
Primer direction
and primer Sequence
Forward
sfbI-F1 ..................5-GTCTTTCTTGACAATAACGTGGTAAGCTC-3
sfbI-F2 ..................5-GTAGCCTATGCTGCCGATGAGAAG-3
sfbI-F3 ..................5-TTTGTACCAGAAAATCCCCCTAAACCTG-3
sfbI-F4 ..................5-GACTTACCTATTGAAGATCCTCGTTATGAG-3
sfbI-F5 ..................5-GCATGCGCGGGTGCTATCG-3
sfbI-F7 ..................5-GTACAGAATATGTACAAGATAATCC-3
sfbI-S1F ................5-GTGCTGAATATGTACCTGATAGTCC-3
PCRP1 .................5-TATCAAAATCTTCTAAGTGCTGAG-3
rofA-F ...................5-GCCAATAACTGAGGTAGC-3
Reverse
sfbI-R1..................5-CTCATAACGAGGATCTTCAATAGGTAAGTC-
3
sfbI-R2..................5-CACTCCTGGCTCTTTCGTATCTTCTG-3
sfbI-R3..................5-GTATCTTCAACAATGGTCACTGTTTCACTG-3
sfbI-R4..................5-CAGTTATCCACTATTCAGCATATTTGCGC-3
sfbI-R5..................5-CGATAGCACCCGCGCATGC-3
sfbI-R6..................5-GCAGCATAGGCTACTTGACCAAAAC-3
sfbI-R7..................5-GGATTATCTTGTACATATTCTGTAC-3
sfbI-R8..................5-CAGGTCTAGGGGGATCTTCTGGTACAAA-3
sfbI-S1R ...............5-GGACTATCAGGTACATATTCAGCAC-3
PCRP1R ..............5-CTCAGCACTTAGAAGATTTTG-3
rofA-R ..................5-GGTTTTGCTCTTTTAGGT-3
FIG. 1. (A) Positions of primers relative to the two genes. The shading of the SfbI domains is as described in the legend to Fig. 2. The schematic
is not drawn to scale. (B to E) Ethidium bromide-stained 1 or 2% agarose gels showing the results of PCR screening for sfbI and rofA for five
representative strains. (B) Screening for sfbI with primers sfbI-F1 and sfbI-R3; (C) determining the number of fibronectin-binding repeats in SfbI
with primers sfbI-F4 and sfbI-R3; (D) screening for rofA with primers rofA-F and rofA-R; (E) determining arrangement of rofA relative to that of
sfbI with primers rofA-R and sfbI-R6. DNA marker (GeneRuler DNA Ladder Mix, MBI Fermentas) sizes (in kilobases) are shown at the left.
Lanes 1 to 5, GAS strains DSM2071, NS732, NS1132, DRY5, and BSA39, respectively.
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mutations, which are easily identifiable as single nucleotide
changes within otherwise conserved regions, the majority ap-
pear to be due to intergenic recombination. Similar to the emm
gene, this intergenic DNA transfer has generated a gene mo-
saic structure in sfbI. The overall effects at the protein level can
be seen in the amino acid sequence alignments of the various
aromatic amino acid-rich domains (Fig. 4). Aro10 has been
used to illustrate how distinct DNA cassettes, flanked by highly
conserved junction sequences, are shared between otherwise
divergent STs. This type of mosaic allele can be generated only
by horizontal gene transfer between strains.
Conserved structure of sfbI. Despite the high degree of vari-
ation observed, the overall structural properties of SfbI were
conserved. Within the aromatic amino acid-rich domain, the
FIG. 2. Overall schematic of variation seen in SfbI. Decreasing variability of SfbI occurs from the amino-terminal aromatic amino acid-rich
domain (solid black) through the proline-rich region (thin diagonal stripe) and to the proline-rich repeats (thick diagonal stripe) and the functional
fibronectin (Fn)-binding domains (stippled). Narrower bars indicate the deletion or duplication of repeat units. The percent identities observed
in pairwise DNA alignments is shown above each domain. Gaps introduced to aid alignment have been treated as single base changes. The diagram
is not drawn to scale. UFBD, upstream fibronectin-binding domain.
FIG. 3. Alignment of amino acid sequences corresponding to the proline-rich domain of SfbI. The consensus sequence is shown at the top in
boldface with underlining. The proline-rich region has two STs, ProA and ProB. Deletion or duplication events within these STs define the
proline-rich region subtypes. Dots represent identical nucleotides relative to the consensus sequence, and hyphens indicate the positions of
insertions found in particular isolates. The ProB repeats are indicated, and the first true proline-rich repeat is boxed.
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FIG. 4. Alignment of nucleotide sequences corresponding to the aromatic amino acid-rich domain STs. The overall consensus sequence is
shown in boldface with underlining above the alignment, and the translated protein sequence is also shown. Dots represent identical nucleotides
relative to the consensus sequence, and hyphens indicate the positions of insertions found in particular isolates. The gene mosaic structure is
illustrated by using Aro10 as an example (boldface), putative horizontally transferred DNA cassettes are shaded in black, while predicted junctions
are shaded in gray.
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distribution of aromatic amino acids remained relatively un-
changed, and similarly, the distribution of proline residues
within the proline-rich domain remained relatively unchanged.
Over the entire length of the deduced amino acid sequence,
hydrophobicity, average charge, and surface probability plots
were generally conserved among the SfbI proteins from differ-
ent strains. By restriction of comparisons to the aromatic
amino acid- and proline-rich domains, the positively charged
regions remained clustered in the aromatic amino acid-rich
domain, despite sequence variation, with a few peaks in the
proline-rich region before the negatively charged proline-rich
repeats (Fig. 4). The periodicity of the repeat sequences is
apparent in hydrophobicity, charge, and surface probability
plots (data not shown). The theoretical pI of the putative SfbI
proteins ranged between 4.11 and 4.81 (mean  standard de-
viation, 4.51  0.13), indicating that SfbI would have a net
negative charge at physiological pH.
Summary of sfbI STs. Thirty-five individual sfbI STs were
identified on the basis of combinations of aromatic amino acid-
and proline-rich domain STs and the numbers of proline-rich
and fibronectin-binding repeats (Table 1). The strains within
some VTs (VT2.2, VT14.1, VT22, VT33.1, VT33.2, VT52,
VT57, and VT61) appeared to be clonal and were of the same
emm and sfbI STs. M12 strain A735 (6) is also likely a clone of
VT52, since all three strains are M12 and have identical sfbI
genes. By contrast, VT37.1 was highly heterogeneous and in-
cluded strains exhibiting sfbI STs 5, 11, 30, and 31. Conversely,
other strains had virtually identical sfbI genes but belonged to
different VTs; for example, sfbI ST18 included strains of
VT2.1, VT2.2, and VT3.1. Some sfbI STs were identical except
in the variable numbers of repeats; for example, sfbI ST30 and
sfbI ST31 were identical except that the former has three pro-
line-rich repeats and one fibronectin-binding repeat, while the
latter has one and two repeats, respectively. This demonstrates
that while the presence of sfbI is associated with VT, the
species of the sfbI allele may be independent.
No correlation between the relative numbers of proline-rich
and fibronectin-binding repeats was observed. There was also
no apparent relationship between the numbers of repeats and
aromatic amino acid- or proline-rich STs; for example, com-
pare sfbI STs 4 to 8 within Aro2 (Table 1). Proline-rich domain
STs were associated with particular aromatic amino acid-rich
domain STs; however, several proline-rich domain sequence
subtypes could be seen to be associated with a single aromatic
amino acid-rich domain ST. For example, within Aro7, sfbI
ST16, sfbI ST17, and sfbI ST18 exhibit proline-rich subtypes
ProB3, ProB2, and ProB1, respectively.
Phylogenic analysis of sfbI. The aromatic amino acid-rich
domain was considered to be the greater indicator of related-
ness, since the high degree of variability of this domain ap-
peared to have been generated by many individual mutations,
while the variability in the numbers of repeats was due to a
smaller number of mutation events that occurred at a relatively
high frequency but that involved large fragments of highly
conserved DNA. This is probably best illustrated by the Aro6
group, the sequences of which are highly conserved in the
aromatic amino acid-rich domain but which contain 0, 1, or 2
internal ProB repeats; 4 or 11 proline-rich repeats; and 1, 2, or
4 fibronectin-binding repeats. This suggests that the repetitive
units are frequently shuffled and that this has little or no true
bearing on the phylogeny of the strain. Variation in sfbI has
arisen through genetic exchange evolution of different alleles
and is not independent. Therefore, a phylogenic tree was not
generated, since the principal assumption of such analysis is
that the alleles have evolved independently.
Is the sfbI ST associated with the clinical source of the
isolate? Information on the clinical sources of the isolates was
available. Clonal distribution indicated that the skin was the
principal reservoir for invasive disease isolates in the Northern
Territory of Australia. Some sfbI STs were exclusively throat
isolates (1, 9, 14, 21, 22); however, this association did not
extend to Aro or proline-rich types. Further investigation re-
vealed that all throat isolates were cultured from samples from
nonindigenous people; therefore, this observation was proba-
bly due to the differences in the strains circulating in the two
populations rather than to the tissue tropism that might be
attributed to the SfbI variants. Overall, there was no common
trend to indicate that particular or related STs were associated
with the clinical sources of the isolates.
DISCUSSION
Components of both the Vir regulon and the FCT region
have undergone frequent genetic rearrangement. These re-
gions encode important virulence factors, principally adhesins
with affinities for different human proteins such as fibronectin,
plasminogen, collagen, fibrinogen, and immunoglobulins. Hor-
izontal gene transfer has played a major role in the generation
of variability within both regions, resulting in the mosaic alleles
seen in emm/enn and sfbI.
The advantages of increased variability through horizontal
gene transfer include the generation of antigenic variation and
variable binding capabilities. As a mechanism of generating
genetic diversity, horizontal gene transfer has the unique ad-
vantage of allowing incorporation of cassettes or domains
which have already been checked for fitness in another genetic
context. This bypasses the less efficient trial-and-error strategy
and is particularly useful in altering the functional capabilities
of a protein in a relatively short time frame.
The mosaic structure of the genes encoding the M-protein
family has resulted in a divergent group of proteins exhibiting
variable binding abilities and serotype-specific epitopes. The
role that such variation plays in the pathogenesis of GAS is
purely speculative; however, clear links have been shown be-
tween Vir regulon arrangements (emm patterns) and tissue
tropism (5). We have shown that sfbI also has a gene mosaic
structure especially apparent in the amino-terminal aromatic
amino acid-rich domain and have identified 35 distinct sfbI
STs. The biological function of the aromatic amino acid-rich
domain is not known. To date, the reported binding functions
of this domain include fibrinogen binding (20) and a putative
carbohydrate-binding motif (40) which, from our data, appears
to be highly conserved (Fig. 3A). The conserved distribution of
aromatic amino acids within this domain, as well as the appar-
ent intragenomic translocation of a highly homologous domain
into Cpa (30), implies that the domain may have a significant
function. In addition, the fact that the entire domain is present
as a defined unit in Cpa implies that the function(s) and/or
properties of the aromatic amino acid-rich domain require the
whole domain. Despite the high degree of amino acid se-
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quence variability, this domain remains positively charged.
Since the proline-rich domain is predominantly negatively
charged, we speculate that interaction between the two do-
mains may be pivotal to the overall structure or folding of the
native protein.
The other possibility is that variability has arisen in response
to selective pressure from the immune system. Anti-M-protein
antibodies are protective yet are serotype specific (23), as the
protective epitopes reside in the variable amino terminus of
the M protein (1, 7, 18). SfbI is a protective antigen when used
in animal infection models (14); however, unlike M protein the
protective epitope(s) resides in the conserved carboxy termi-
nus and can provide protection from heterologous challenge
(34). Natural infection in individuals from populations in
which streptococcal infections are endemic also elicits signifi-
cant levels of anti-SfbI IgG antibodies (13). Since these indi-
viduals are still infected, despite the presence of anti-SfbI IgG
antibodies, it appears that anti-SfbI antibodies either are not
protective in humans or are not present in significantly high
enough concentrations to be effective. While the fibronectin-
binding domain is protective and conserved, variability in the
amino terminus may represent a mechanism of immune eva-
sion, thereby directing the immune response away from the
carboxy terminus.
Recombination within selection-neutral genes in GAS is
common to the point that it masks phylogenic signals (10). As
a consequence, phylogenic analyses of sfbI do not clarify evo-
lutionary relationships between strains but clarify only the sim-
ilarities between sfbI alleles. In looking at possible correlations
between the sfbI STs and the clinical sources of the isolates, we
did not find any associations. As with T-agglutination patterns,
specific sfbI STs were consistently associated with emm STs;
however, like T types, they were not restricted to singular emm
STs. This seems to indicate that emm and sfbI and not closely
linked. Given that the tee and sfbI genes both reside in the FCT
region, it would be interesting to determine if T types and sfbI
STs are more closely associated with each other than with emm
STs. Such an analysis would require determination of the T
types of the 54 GAS strains examined in this study.
The 34 individual sfbI STs identified in this study seem to
have evolved through a combination of different evolutionary
mechanisms working independently on distinct regions of the
sfbI gene. The majority of divergence in the Aro domain ap-
pears to be due to intergenic recombination of horizontally
transferred DNA cassettes, resulting in a genetic mosaic; two
distinct and divergent STs are apparent in the central proline-
rich region of sfbI; and the deletion or duplication of repeat
units has resulted in a variable number of ProB, proline-rich,
and fibronectin-binding repeats.
SfbI is an important virulence factor involved in colonization
and internalization in fibronectin-rich epithelial tissues such as
the upper respiratory mucosa and injured skin epithelium.
Without clear associations between SfbI variants and function
or tissue tropism, it is impossible to draw conclusions regarding
the selective factors influencing these evolutionary mecha-
nisms; however, the variability observed implies significant se-
lective pressure on this locus in vivo. In light of the role played
by intergenic transfer in the generation of variability in ligand-
binding capacities in members of the M-protein family, the
implications for microbial pathogenesis of possible functional
and antigenic variability in SfbI warrant further investigation.
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